GB491 Combined With Fulvestrant for HR+ HER2- Locally Advanced or Metastatic Breast Cancer
GB491-004 is a multicenter, randomized, double-blind, placebo-controlled Phase III study to evaluate the efficacy and safety of GB491 in combination with fulvestrant in patients with HR-positive, HER2-negative locally advanced or metastatic breast cancer who have progressed on prior endocrine therapy.
Locally Advanced or Metastatic Breast Cancer
DRUG: GB491+ Fulvestrant|DRUG: Placebo+Fulvestrant
PFS assessed by the investigator, To assess the PFS assessed by the investigator, Approximately 1.5 years
PFS assessed by the blinded independent central review (BICR), To assess the PFS assessed by the BICR, Approximately 1.5 years|OS, To assess the overall survival (OS), Approximately 3 years|ORR, To assess the objective response rate (ORR), Approximately 1.5 years|DOR, To assess the duration of response, Approximately 1.5 years|DCR, To assess the disease control rate, Approximately 1.5 years|CBR, To assess the clinical benefit rate, Approximately 1.5 years|Safety and tolerability, To assess the safety and tolerability assessed by incidence and severity of adverse events (AEs) and serious AEs (SAEs) according to NCI-CTCAE version 5.0, Approximately 3 years|PK, To assess the PK assessed by population pharmacokinetic analysis based on plasma concentrations of GB491, From Cycle 1 to Cycle 4, approximately 4 months
GB491-004 is a multicenter, randomized, double-blind, placebo-controlled Phase III study to evaluate the efficacy and safety of GB491 in combination with fulvestrant in patients with HR-positive, HER2-negative locally advanced or metastatic breast cancer who have progressed on prior endocrine therapy.